Precision BioSciences Inc., a clinical stage gene editing company, will be attending the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, Louisiana, from May 13-17, 2025. At the event, they will present five abstracts detailing their _in vivo_ gene editing programs, including data from their lead program PBGENE-HBV for chronic hepatitis B, and partner iECURE's ECUR-506 for OTC deficiency. Additional presentations will cover preclinical results from muscle programs targeting mitochondrial disease and Duchenne Muscular Dystrophy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。